» Articles » PMID: 34893592

Distinct Roles of KLF4 in Mesenchymal Cell Subtypes During Lung Fibrogenesis

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Dec 11
PMID 34893592
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

During lung fibrosis, the epithelium induces signaling to underlying mesenchyme to generate excess myofibroblasts and extracellular matrix; herein, we focus on signaling in the mesenchyme. Our studies indicate that platelet-derived growth factor receptor (PDGFR)-β cells are the predominant source of myofibroblasts and Kruppel-like factor (KLF) 4 is upregulated in PDGFR-β cells, inducing TGFβ pathway signaling and fibrosis. In fibrotic lung patches, KLF4 is down-regulated, suggesting KLF4 levels decrease as PDGFR-β cells transition into myofibroblasts. In contrast to PDGFR-β cells, KLF4 reduction in α-smooth muscle actin (SMA) cells non-cell autonomously exacerbates lung fibrosis by inducing macrophage accumulation and pro-fibrotic effects of PDGFR-β cells via a Forkhead box M1 to C-C chemokine ligand 2-receptor 2 pathway. Taken together, in the context of lung fibrosis, our results indicate that KLF4 plays opposing roles in PDGFR-β cells and SMA cells and highlight the importance of further studies of interactions between distinct mesenchymal cell types.

Citing Articles

Single-Cell RNA-Sequencing Identifies Bone Marrow-Derived Progenitor Cells as a Main Source of Extracellular Matrix-Producing Cells Across Multiple Organ-Based Fibrotic Diseases.

Zhong Y, Wei B, Wang W, Chen J, Wu W, Liang L Int J Biol Sci. 2024; 20(13):5027-5042.

PMID: 39430238 PMC: 11488580. DOI: 10.7150/ijbs.98839.


Krüppel-like factors family in health and disease.

Xiang T, Yang C, Deng Z, Sun D, Luo F, Chen Y MedComm (2020). 2024; 5(9):e723.

PMID: 39263604 PMC: 11387732. DOI: 10.1002/mco2.723.


Comprehensive transcription factor perturbations recapitulate fibroblast transcriptional states.

Southard K, Ardy R, Tang A, OSullivan D, Metzner E, Guruvayurappan K bioRxiv. 2024; .

PMID: 39131349 PMC: 11312553. DOI: 10.1101/2024.07.31.606073.


Spatial and phenotypic heterogeneity of resident and monocyte-derived macrophages during inflammatory exacerbations leading to pulmonary fibrosis.

Moos P, Cheminant J, Cowman S, Noll J, Wang Q, Musci T Front Immunol. 2024; 15:1425466.

PMID: 39100672 PMC: 11294112. DOI: 10.3389/fimmu.2024.1425466.


Optimized rAAV8 targeting acinar KLF4 ameliorates fibrosis in chronic pancreatitis via exosomes-enriched let-7s suppressing pancreatic stellate cells activation.

Zhao Y, Feng Y, Sun F, Li L, Chen J, Song Y Mol Ther. 2024; 32(8):2624-2640.

PMID: 38956871 PMC: 11405174. DOI: 10.1016/j.ymthe.2024.06.030.


References
1.
Blackwell T, Tager A, Borok Z, Moore B, Schwartz D, Anstrom K . Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med. 2013; 189(2):214-22. PMC: 3983890. DOI: 10.1164/rccm.201306-1141WS. View

2.
Kropski J, Blackwell T . Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis. Annu Rev Med. 2019; 70:211-224. PMC: 6378692. DOI: 10.1146/annurev-med-041317-102715. View

3.
Martinez F, Safrin S, Weycker D, Starko K, Bradford W, King Jr T . The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005; 142(12 Pt 1):963-7. DOI: 10.7326/0003-4819-142-12_part_1-200506210-00005. View

4.
Ley B, Collard H, King Jr T . Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 183(4):431-40. DOI: 10.1164/rccm.201006-0894CI. View

5.
Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View